| [ Summary ] |
Bisphosphonate is an anti-osteoporotic agent with a full history of clinical evidence. Its effects have a significant impact on public health. Bisphosphonate induces a selective dysfunction in osteoclasts, which induces bone mass gain. However, bisphosphonate related osteoclastic dysfunction can also induce abnormalities in systemic mineral metabolism including the exacerbation of hyperparathyroidism in patients with chronic kidney disease. The risk of adverse effects associated with bisphosphonate accumulation in bone tissue has not been fully assessed, either. Thus, aggressive use for patients with chronic kidney disease is not recommended, at this time. |